Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.
Drug Treatment Study for Recurrent or Progressive Glioblastoma
The main purpose of this phase II study is to compare the effectiveness of treatment with DSP 7888 in combination with bevacizumab versus bevacizumab alone in patients with glioblastoma (GBM). Bevacizumab has been approved by the U.S. Food and Drug Administration (FDA) to treat GBM. DSP-7888 is not approved for use by the FDA, although it has allowed the drug to be tested in studies such as this one.
Another purpose of this study is to learn more about a newly discovered experimental vaccine drug, DSP-7888 Dosing Emulsion (or simply DSP-7888), that is being tested in people with your type of cancer. This drug may help the immune system to fight against cancer cells that have a protein called WT1 (Wilms’ Tumor 1 gene). It is hoped that with the administration of DSP-7888 the immune system may be able to kill or slow down the growth of cancer cells.
In order to participate you must meet the following criteria:
- Have a diagnosis of glioblastoma.
- Have evidence of recurrence or progression of disease.
- Have recovered from effects of all prior therapies.
You will be excluded from the study if any of the following criteria apply to you:
- Have received prior Bevacizumab therapy.
- Have received anti-neoplastic therapy, including RT, for first relapse or recurrence.
This is a partial list of inclusion and exclusion criteria.